The pharmaceutical industry focused on sclerostin as a therapeutic target based on the expression of sclerostin being almost exclusive in bone tissue, the progressive increase in bone mass in adults with sclerosteosis and Van Buchem disease and on the absence of non-skeletal clinical features in these patients (167). The gene discussed is SOST; the disease is sclerosteosis.